Bio
Ben has been working as a medicinal chemist since 2011. After completing his postdoc, he joined Novartis, where he conducted discovery-phase research for oncology indications. While at Novartis, he transitioned to infectious disease drug discovery. He then joined Via Nova Therapeutics, a Novartis antiviral spinout founded by Don Ganem and Kelly Wong, when Novartis exited the infectious disease space.
Drug Discovery
构效关系 (SAR) 研究的挑战与机遇
在本期 CAS 系列文章《药物开发的挑战与机遇》中，我们与 Via Nova Therapeutics 的化学高级总监 Ben Taft 讨论了构效关系研究和生物活性数据的潜在前沿。